CAS 112966-16-2: Spiro[3H-3a,6-ethanoisobenzofuran-4(1H),1'(3'H)-isobenzofuran]-1,3'-dione,3-butylidene-5,6,6',7'-tetrahydro-5-propyl-, (1'S,3Z,3aS,5R,6R)-

Tokinolide B may have sedative and spasmolytic properties.

Tokinolide B is a secondary metabolite, which is a naturally occurring compound derived from marine cyanobacteria. These microorganisms are prolific producers of a diverse array of bioactive metabolites, often possessing unique structural properties that inspire scientific investigation. Tokinolide B has been identified for its intriguing mode of action, primarily its anti-inflammatory effects, which are thought to be mediated through the modulation of specific cellular signaling pathways involved in inflammation. Research into Tokinolide B has unveiled its potential applications in biomedical fields, particularly in developing therapeutic agents targeting inflammatory diseases. Studies have focused on its ability to inhibit pro-inflammatory cytokine production, offering insights into its prospective use in treating conditions such as arthritis and other inflammatory disorders. Although still under investigation, its unique properties could pave the way for novel applications in drug development. Scientists continue to explore its full potential, aiming to elucidate more detailed mechanisms of action and therapeutic efficacy.